Literature DB >> 23026823

Trametinib for patients with advanced melanoma.

Shigeo Masuda, Juan Carlos Izpisua Belmonte.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23026823     DOI: 10.1016/S1470-2045(12)70419-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

1.  Oncology in 2012: from personalized medicine to precision medicine.

Authors:  J F Morere
Journal:  Target Oncol       Date:  2012-11-22       Impact factor: 4.493

2.  Identification of WEE1 as a target to make AKT inhibition more effective in melanoma.

Authors:  Omer F Kuzu; Raghavendra Gowda; Arati Sharma; Mohammad A Noory; Gregory Kardos; SubbaRao V Madhunapantula; Joseph J Drabick; Gavin P Robertson
Journal:  Cancer Biol Ther       Date:  2017-11-30       Impact factor: 4.742

3.  Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma.

Authors:  Yibing Yan; Matthew J Wongchenko; Caroline Robert; James Larkin; Paolo A Ascierto; Brigitte Dréno; Michele Maio; Claus Garbe; Paul B Chapman; Jeffrey A Sosman; Zhen Shi; Hartmut Koeppen; Jessie J Hsu; Ilsung Chang; Ivor Caro; Isabelle Rooney; Grant A McArthur; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2019-03-01       Impact factor: 12.531

4.  Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.

Authors:  P B Chapman; C Robert; J Larkin; J B Haanen; A Ribas; D Hogg; O Hamid; P A Ascierto; A Testori; P C Lorigan; R Dummer; J A Sosman; K T Flaherty; I Chang; S Coleman; I Caro; A Hauschild; G A McArthur
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.